# Safety And Tolerability Of Subcutaneous MANP In Difficult To Control/Resistant Hypertensive Subjects

> **NCT05247528** · PHASE1 · COMPLETED · sponsor: **E-Star BioTech, LLC** · enrollment: 37 (actual)

## Conditions studied

- Resistant Hypertension
- Difficult to Control Hypertension

## Interventions

- **DRUG:** MANP
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05247528
- **Lead sponsor:** E-Star BioTech, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-12-20
- **Primary completion:** 2022-10-31
- **Final completion:** 2022-10-31
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2022-11-29

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05247528

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05247528, "Safety And Tolerability Of Subcutaneous MANP In Difficult To Control/Resistant Hypertensive Subjects". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05247528. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*